GF Fund Management CO. LTD. Makes New $1.44 Million Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

GF Fund Management CO. LTD. bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 23,035 shares of the company's stock, valued at approximately $1,436,000. GF Fund Management CO. LTD. owned 0.07% of TransMedics Group at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group in the 4th quarter valued at approximately $31,000. Hager Investment Management Services LLC acquired a new position in TransMedics Group during the fourth quarter worth about $33,000. Sachetta LLC acquired a new position in TransMedics Group during the fourth quarter worth about $40,000. AlphaQuest LLC purchased a new position in TransMedics Group in the 4th quarter worth about $52,000. Finally, Arcadia Investment Management Corp MI purchased a new position in TransMedics Group in the 4th quarter worth about $72,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Stock Performance

NASDAQ TMDX traded up $0.09 during midday trading on Wednesday, hitting $128.62. The company had a trading volume of 598,706 shares, compared to its average volume of 1,357,511. The firm has a fifty day simple moving average of $91.84 and a two-hundred day simple moving average of $77.79. The stock has a market cap of $4.35 billion, a price-to-earnings ratio of 136.83 and a beta of 1.91. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $143.54 million for the quarter, compared to the consensus estimate of $123.39 million. During the same period last year, the business earned $0.35 earnings per share. The firm's revenue for the quarter was up 48.2% compared to the same quarter last year. Equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. Needham & Company LLC reissued a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Oppenheimer lifted their target price on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Piper Sandler restated an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, TransMedics Group presently has an average rating of "Moderate Buy" and a consensus price target of $126.70.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at approximately $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares of the company's stock, valued at $1,503,159.92. The trade was a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.